Tackling Treatment-Refractory and Drug-Resistant CMV in the Solid Organ Transplant Setting: A Care Team Forum®

Program Overview

The goal of this activity is to provide clinicians with the clinical tools necessary to identify and manage treatment-refractory and drug-resistant CMV in patients after solid organ transplantation (SOT). A panel of infectious diseases experts review current CMV treatment guidelines, discuss antiviral resistance testing, and provide insights for management with a new antiviral therapeutic option. An experienced patient with CMV provides important practical take-aways for clinicians to use with their own SOT patients

0.75 CE Credit(s)
Expires: April 12, 2024

Target Audience

Transplantation, infectious diseases, nephrology, internal medicine, and pharmacy clinicians who manage patients with refractory or resistant cytomegalovirus (CMV) after solid organ transplantation.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Employ current CMV treatment guidelines for the use of antiviral therapies and management of their adverse effects 
  • Identify treatment-refractory and drug-resistant CMV by correctly interpreting antiviral resistance testing results
  • Select transplant patients who will benefit from the efficacy and reduced toxicity of new CMV therapy 

Activity Faculty

Humar, Atul- Headshot

Atul Humar, MD, MSc, FRCPC, FAST

Professor, Department of Medicine
University of Toronto
R. Fraser Elliott Chair, Transplantation
University Health Network
Director, University of Toronto Transplant Institute
Toronto, Ontario, Canada


Raymund R. Razonable, MD, FIDSA, FAST

Professor, Medicine
Program Director, Infectious Diseases Fellowship Program
Vice Chair, Division of Infectious Diseases
Mayo Clinic
Rochester, Minnesota, United States

62-22-1045 CMV Faculty Headshot-SILVEIRA_FERNANDA

Fernanda P. Silveira, MD, MS, FIDSA, FAST

Director, Clinical Operations
Transplant Infectious Diseases
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States


Provider Statement

Provided by RMEI Medical Education, LLC.

Supporter Statement

Supported by an educational grant from Takeda Pharmaceuticals, U.S.A., Inc.

Disclosure of Financial Relationships 

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. 


Atul Humar, MD, MSc, FRCPC, FAST, has relevant financial relationships with Astellas Pharma, Inc.; Roche; Takeda (Consultant).

Raymund R. Razonable, MD, FIDSA, FAST, has relevant financial relationships with Gilead Sciences, Inc.; Regeneron; Roche (Research); AlloVir (Data Adjudication Committee); Novartis (Data Safety Monitoring Board).

Fernanda P. Silveira, MD, MS, FIDSA, FAST, has relevant financial relationships with Eurofins Viracor; Janssen Pharmaceuticals; Takeda (Consultant); Ansun Biopharma; Merck; Regeneron; Takeda (Research).



Patient participating in this activity has no relevant financial relationships.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers

RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement 

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Credit Designation

For Physicians 
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Pharmacists
RMEI Medical Education, LLC designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number – JA4008290-0000-23-005-H01-P)
Type of Activity: Knowledge

Instructions for Participation and Credit 

To receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected]. 

Users must: 

  • Read the learning objectives and faculty disclosures 
  • Participate in the activity 
  • Complete the activity evaluation

There is no fee to participate. 



*The expense for this gift card is solely funded by RMEI Medical Education, LLC. 
No supporter funding was used for the expense of this gift card. 

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.   

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2023. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | www.RMEI.com | (866) 770-RMEI


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources